All Relations between Neurodegenerative Diseases and dopaminergic

Publication Sentence Publish Date Extraction Date Species
Kwang Soo Kim, Yu Ree Choi, Ji-Young Park, Jung-Ho Lee, Dong Kyu Kim, Seung-Jae Lee, Seung R Paik, Ilo Jou, Sang Myun Par. Proteolytic cleavage of extracellular α-synuclein by plasmin: implications for Parkinson disease. The Journal of biological chemistry. vol 287. issue 30. 2012-10-18. PMID:22619171. parkinson disease (pd) is the second most common neurodegenerative disease characterized by a progressive dopaminergic neuronal loss in association with lewy body inclusions. 2012-10-18 2023-08-12 human
Ronald B Postuma, Jean-Francois Gagnon, Jacques Y Montplaisi. REM sleep behavior disorder: from dreams to neurodegeneration. Neurobiology of disease. vol 46. issue 3. 2012-09-14. PMID:22019718. recent studies in idiopathic rbd patients have demonstrated that olfaction, color vision, severity of rem atonia loss, transcranial ultrasound of the substantia nigra, and dopaminergic neuroimaging can predict development of neurodegenerative disease. 2012-09-14 2023-08-12 Not clear
Mari Teraoka, Kazuhiro Nakaso, Chiaki Kusumoto, Satoshi Katano, Naoko Tajima, Atsushi Yamashita, Teppei Zushi, Satoru Ito, Tatsuya Matsur. Cytoprotective effect of chlorogenic acid against α-synuclein-related toxicity in catecholaminergic PC12 cells. Journal of clinical biochemistry and nutrition. vol 51. issue 2. 2012-09-11. PMID:22962530. parkinson's disease is a major neurodegenerative disease involving the selective degeneration of dopaminergic neurons and α-synuclein containing lewy bodies formation in the substantia nigra. 2012-09-11 2023-08-12 Not clear
Ryan M Welchko, Xavier T Lévêque, Gary L Dunba. Genetic rat models of Parkinson's disease. Parkinson's disease. vol 2012. 2012-08-23. PMID:22550609. parkinson's disease (pd) is a neurodegenerative disease characterized by a specific loss of dopaminergic neurons. 2012-08-23 2023-08-12 rat
Vigneshwaran Pitchaimani, Somasundaram Arumugam, Rajarajan A Thandavarayan, Manisenthilkumar K Thiyagarajan, Rajasekaran Aiyalu, Remya Sreedhar, Takashi Nakamura, Kenichi Watanab. Nootropic activity of acetaminophen against colchicine induced cognitive impairment in rats. Journal of clinical biochemistry and nutrition. vol 50. issue 3. 2012-08-23. PMID:22573928. acetaminophen has gaining importance in neurodegenerative diseases by attenuating the dopaminergic neurodegeneration in caenorhabditis elegans model, decreasing the chemokines and the cytokines and increasing the anti apoptotic protein such as bcl-2 in neuronal cell culture. 2012-08-23 2023-08-12 rat
Mercedes Unzeta, Elisenda San. Novel MAO-B inhibitors: potential therapeutic use of the selective MAO-B inhibitor PF9601N in Parkinson's disease. International review of neurobiology. vol 100. 2012-07-24. PMID:21971010. parkinson's disease (pd) is a neurodegenerative disease that is characterized by preferential loss of dopaminergic neurons in the substantia nigra pars compacta, leading to declining levels of dopamine in the striatum. 2012-07-24 2023-08-12 Not clear
Hongyan Zhou, Jie Chen, Xilin Lu, Cunzhou Shen, Jinsheng Zeng, Ling Chen, Zhong Pe. Melatonin protects against rotenone-induced cell injury via inhibition of Omi and Bax-mediated autophagy in Hela cells. Journal of pineal research. vol 52. issue 1. 2012-06-18. PMID:21883444. parkinson's disease is the second most common neurodegenerative disease, and environmental toxins such as rotenone play an important role in causing degeneration of dopaminergic neurons. 2012-06-18 2023-08-12 Not clear
Ruiping Xia, Zhi-Hong Ma. Progression of motor symptoms in Parkinson's disease. Neuroscience bulletin. vol 28. issue 1. 2012-05-04. PMID:22233888. parkinson's disease (pd) is a chronic progressive neurodegenerative disease that is clinically manifested by a triad of cardinal motor symptoms - rigidity, bradykinesia and tremor - due to loss of dopaminergic neurons. 2012-05-04 2023-08-12 Not clear
Kai Loewenbrück, Alexander Storc. Stem cell-based therapies in Parkinson's disease: future hope or current treatment option? Journal of neurology. vol 258. issue Suppl 2. 2012-03-25. PMID:21437664. parkinson's disease (pd) is one of the most frequent neurodegenerative diseases and represents a major therapeutic challenge because of the so far missing therapeutic means to influence the ongoing loss of dopaminergic innervation to the striatum. 2012-03-25 2023-08-12 Not clear
Maria Trinidad Herrero, Javier Pagonabarraga, Gurutz Linazasor. Neuroprotective role of dopamine agonists: evidence from animal models and clinical studies. The neurologist. vol 17. issue 6 Suppl 1. 2012-02-21. PMID:22045327. parkinson disease is a progressive neurodegenerative disease that affects, among other neurotransmitter systems, the nigrostriatal dopaminergic projection. 2012-02-21 2023-08-12 Not clear
Juliane Proft, Jamshid Faraji, Jerrah C Robbins, Fabiola C R Zucchi, Xiaoxi Zhao, Gerlinde A Metz, Janice E A Brau. Identification of bilateral changes in TID1 expression in the 6-OHDA rat model of Parkinson's disease. PloS one. vol 6. issue 10. 2012-02-13. PMID:22016808. parkinson's disease (pd) is a common neurodegenerative disease characterized by the loss of dopaminergic neurons in the substantia nigra and the aggregation of α-synuclein into lewy bodies. 2012-02-13 2023-08-12 rat
Junpeng Zhao, Qunyuan X. Emerging restorative treatments for Parkinson's disease: manipulation and inducement of dopaminergic neurons from adult stem cells. CNS & neurological disorders drug targets. vol 10. issue 4. 2012-01-12. PMID:21495964. parkinson's disease (pd) is a common neurodegenerative disease, characterized by a selective loss of midbrain dopaminergic (da) neurons. 2012-01-12 2023-08-12 human
Hironori Yokoyama, Hayato Kuroiwa, Jiro Kasahara, Tsutomu Arak. Neuropharmacological approach against MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine)-induced mouse model of Parkinson's disease. Acta neurobiologiae experimentalis. vol 71. issue 2. 2011-11-03. PMID:21731080. pd is well known to be a chronic and progressive neurodegenerative disease produced by a selective degeneration of dopaminergic neurons in the substantia nigra pars compacta. 2011-11-03 2023-08-12 mouse
Jie Wu, Chen Wang, Jiao Sun, Yang Xu. Neurotoxicity of silica nanoparticles: brain localization and dopaminergic neurons damage pathways. ACS nano. vol 5. issue 6. 2011-10-26. PMID:21526751. these data demonstrate that sio(2)-nps possibly have a negative impact on the striatum and dopaminergic neurons as well as a potential risk for neurodegenerative diseases. 2011-10-26 2023-08-12 Not clear
In Su Kim, Dong-Kug Choi, Hun Jong Jun. Neuroprotective effects of vanillyl alcohol in Gastrodia elata Blume through suppression of oxidative stress and anti-apoptotic activity in toxin-induced dopaminergic MN9D cells. Molecules (Basel, Switzerland). vol 16. issue 7. 2011-10-24. PMID:21705974. these results indicate that vanillyl alcohol protected dopaminergic mn9d cells against mpp+-induced apoptosis by relieving oxidative stress and modulating the apoptotic process and is therefore a potential candidate for treatment of neurodegenerative diseases such as parkinson's disease. 2011-10-24 2023-08-12 Not clear
Tito Calì, Denis Ottolini, Marisa Brin. Mitochondria, calcium, and endoplasmic reticulum stress in Parkinson's disease. BioFactors (Oxford, England). vol 37. issue 3. 2011-10-14. PMID:21674642. parkinson's disease (pd) is a progressive neurodegenerative disease characterized by a loss of dopaminergic neurons in the substantia nigra pars compacta (snpc) and the presence of intracytoplasmatic inclusions known as lewy bodies, largely composed of alpha-synuclein (α-syn). 2011-10-14 2023-08-12 Not clear
Boyu Li, Yun Zhang, Yuhe Yuan, Naihong Che. A new perspective in Parkinson's disease, chaperone-mediated autophagy. Parkinsonism & related disorders. vol 17. issue 4. 2011-10-10. PMID:21215675. parkinson's disease (pd) is an age-related neurodegenerative disease characterized by loss of dopaminergic neurons and aggregation of alpha-synuclein. 2011-10-10 2023-08-12 Not clear
Ebru Mihci, Sibel S Ozkaynak, Nilgun Sallakci, Ferah Kizilay, Ugur Yavuze. VEGF polymorphisms and serum VEGF levels in Parkinson's disease. Neuroscience letters. vol 494. issue 1. 2011-08-15. PMID:21334418. the aim of the current study is first to demonstrate whether there is an association between the three common vegf polymorphisms (-2578c/a, -634c/g and 936c/t) in the vegf gene and idiopathic parkinson's disease (ipd) which is a neurodegenerative disease caused by the progressive degeneration of nigrostriatal dopaminergic neurons, and second to see if the serum levels of vegf is reduced in the patients with ipd. 2011-08-15 2023-08-12 human
Joe H Pogson, Rachael M Ivatt, Alexander J Whitwort. Molecular mechanisms of PINK1-related neurodegeneration. Current neurology and neuroscience reports. vol 11. issue 3. 2011-08-05. PMID:21331528. pink1 is a mitochondrially targeted kinase that has been linked to a rare monogenic form of parkinson's disease (pd), a common neurodegenerative disease characterized by the degeneration of selected dopaminergic neurons. 2011-08-05 2023-08-12 Not clear
Kumar Sapkota, Seung Kim, Se-Eun Park, Sung-Jun Ki. Detoxified extract of Rhus verniciflua stokes inhibits rotenone-induced apoptosis in human dopaminergic cells, SH-SY5Y. Cellular and molecular neurobiology. vol 31. issue 2. 2011-07-18. PMID:21061154. these results suggest that rvs may protect dopaminergic neurons against rotenone-induced apoptosis by multiple functions and contribute to neuroprotection in neurodegenerative diseases, such as pd. 2011-07-18 2023-08-12 human